QS Investors LLC lessened its stake in PTC Therapeutics (NASDAQ:PTCT) by 3.7% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 220,818 shares of the biopharmaceutical company’s stock after selling 8,520 shares during the quarter. QS Investors LLC owned about 0.53% of PTC Therapeutics worth $3,683,000 at the end of the most recent reporting period.
Other hedge funds also recently bought and sold shares of the company. Oppenheimer & Co. Inc. raised its stake in PTC Therapeutics by 15.9% during the fourth quarter. Oppenheimer & Co. Inc. now owns 17,493 shares of the biopharmaceutical company’s stock worth $292,000 after acquiring an additional 2,400 shares in the last quarter. Rhumbline Advisers raised its stake in PTC Therapeutics by 8.6% during the third quarter. Rhumbline Advisers now owns 42,103 shares of the biopharmaceutical company’s stock worth $842,000 after acquiring an additional 3,335 shares in the last quarter. Public Employees Retirement System of Ohio raised its stake in PTC Therapeutics by 49.5% during the third quarter. Public Employees Retirement System of Ohio now owns 11,582 shares of the biopharmaceutical company’s stock worth $232,000 after acquiring an additional 3,835 shares in the last quarter. Macquarie Group Ltd. acquired a new position in PTC Therapeutics during the third quarter worth about $102,000. Finally, California State Teachers Retirement System raised its stake in PTC Therapeutics by 8.7% during the third quarter. California State Teachers Retirement System now owns 64,160 shares of the biopharmaceutical company’s stock worth $1,284,000 after acquiring an additional 5,119 shares in the last quarter. 91.81% of the stock is owned by institutional investors and hedge funds.
Several research analysts have commented on PTCT shares. Zacks Investment Research raised PTC Therapeutics from a “hold” rating to a “buy” rating and set a $19.00 target price for the company in a research note on Thursday, January 4th. ValuEngine upgraded PTC Therapeutics from a “strong sell” rating to a “sell” rating in a report on Tuesday, January 9th. Royal Bank of Canada started coverage on PTC Therapeutics in a report on Monday, January 29th. They set a “sector perform” rating on the stock. Barclays restated a “hold” rating on shares of PTC Therapeutics in a report on Tuesday, January 23rd. Finally, William Blair restated a “hold” rating on shares of PTC Therapeutics in a report on Wednesday, March 7th. Three research analysts have rated the stock with a sell rating, five have assigned a hold rating and three have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and a consensus price target of $23.86.
PTCT stock traded down $0.33 during trading on Friday, hitting $25.70. The company had a trading volume of 527,999 shares, compared to its average volume of 1,155,289. PTC Therapeutics has a one year low of $9.57 and a one year high of $33.22. The stock has a market capitalization of $1,176.96, a PE ratio of -12.72 and a beta of 1.66. The company has a debt-to-equity ratio of 0.93, a current ratio of 3.04 and a quick ratio of 2.90.
PTC Therapeutics (NASDAQ:PTCT) last announced its earnings results on Tuesday, March 6th. The biopharmaceutical company reported $0.03 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.14) by $0.17. PTC Therapeutics had a negative return on equity of 50.75% and a negative net margin of 40.64%. The business had revenue of $78.00 million for the quarter, compared to analysts’ expectations of $78.59 million. During the same period in the prior year, the business posted ($0.78) earnings per share. The firm’s revenue was up 209.5% on a year-over-year basis. research analysts expect that PTC Therapeutics will post -1.4 earnings per share for the current year.
WARNING: This piece of content was reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this piece of content on another domain, it was copied illegally and republished in violation of international trademark & copyright laws. The correct version of this piece of content can be accessed at https://www.dispatchtribunal.com/2018/04/08/ptc-therapeutics-inc-ptct-stake-lowered-by-qs-investors-llc.html.
PTC Therapeutics Profile
PTC Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines for the treatment of rare disorders. The company offers Translarna (ataluren) for the treatment of nonsense mutation Duchenne muscular dystrophy in ambulatory patients; and Emflaza (deflazacort) for treating Duchenne muscular dystrophy.
Receive News & Ratings for PTC Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PTC Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.